Teijin Pharma and Takeda Pharmaceutical Company have announced that Teijin Pharma’s US licensee for febuxostat and Takeda’s wholly owned subsidiary, Takeda Pharmaceuticals North America, has received the FDA’s
Roche has announced that a Phase III study investigating the efficacy and safety of extended preventative therapy with Valcyte met its primary endpoint of reducing the number of
Under the terms of one of two types of purchase agreements, Affymax will sell 2.84 million newly issued shares of its common stock at a purchase price of
Dr Zucconi replaces David Platt, who will become CEO and chief technology officer of Medi-Pharmaceuticals, a company that is 10% owned by Pro-Pharmaceuticals that is engaged in developing
In the fourth quarter of 2008, the company recorded net revenue of $459.3 million compared to net revenue of $288.0 million in the fourth quarter of 2007, an
Celera reported net revenues of $47.3 million for the fourth quarter of calendar 2008 that ended December 27, 2008, compared to $40.3 million in the prior year quarter.
BioMarin and partner La Jolla Pharmaceutical have decided to stop the study, unblind the data and evaluate all of the clinical results including secondary endpoints such as systemic
Recent corporate highlights: Increased revenue from core products, which excludes therapeutic grade human serum albumin products, by 3%, or $0.2 million, in the first fiscal quarter of 2009
Vical had cash and investments of about $42 million at year-end 2008, including about $5 million invested in long-term auction rate securities. For the fourth quarter of 2008,
The Sandoz product is approved for the same range of indications as the reference product, Neupogen and offers patients comparable quality, safety and efficacy combined with greater cost-effectiveness.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.